Workforce-Focused Analysis on GLP-1s: Research Findings and Methodology

Aon GLP-1 Research Findings
Research Findings and Methodology

Workforce-Focused Analysis on GLP-1s

GLP-1 (glucagon-like peptide-1) medications have demonstrated positive outcomes in treating obesity, type 2 diabetes and related comorbidities. However, their high cost on individual consumers and employers have drawn considerable attention. To help employers better understand the impact of GLP-1s on medical spend over time, how these medications improve health outcomes for their workforce and to make coverage decisions, Aon conducted an independent study to bridge clinical studies and cost impact studies.

This overview summarizes key findings from Aon’s workforce-focused GLP-1 research analysis, which examines claims data from over 50 million commercially insured lives, including over 139,000 prescribed users of second-generation GLP-1s from 2022-2024.

Aon GLP-1 Research Findings

Ready to Explore Further?

Download the Workforce-Focused Analysis on GLP-1s Report

Subscribe CTA Banner